Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder (Q33874761)

29 July 2017

Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder (English)

1 reference

29 July 2017

0 references

placebo-controlled trial

1 reference

1 reference

Pande AC

1

1 reference

29 July 2017

Greiner M

2

1 reference

29 July 2017

Adams JB

3

1 reference

29 July 2017

Lydiard RB

4

1 reference

29 July 2017

Pierce MW

5

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 September 1999

1 reference

29 July 2017

Biological Psychiatry

1 reference

29 July 2017

46

1 reference

29 July 2017

6

1 reference

29 July 2017

860-862

1 reference

Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses.

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900090-6

A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900090-6

Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and "mixed" CCK-A/CCK-B antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900090-6

The cholecystokinin hypothesis of anxiety and panic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900090-6

The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900090-6

Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900090-6

Lymphocyte cholecystokinin concentrations in panic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900090-6

Failure of CCK receptor ligands to modify anxiety-related behavioural suppression in an operant conflict paradigm in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900090-6

Lack of effect of CCKB receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900090-6

A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900090-6

CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900090-6

The CCK-B antagonist LY288513 blocks effects of diazepam withdrawal on auditory startle.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900090-6

Evidence for an involvement of the brain cholecystokinin B receptor in anxiety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900090-6

Effect of the cholecystokinin-B receptor antagonist L-365,260 on lactate-induced panic attacks in panic disorder patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900090-6

Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900090-6

The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900090-6

10.1016/S0006-3223(99)00090-6

7 January 2021

Identifiers

DOI

1 reference

29 July 2017

1 reference